Business Wire: September 26, 2016 – CAMBRIDGE, MA, U.S.A. – Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the company will focus its resources on its proprietary GalXC™ technology platform to advance…
